Wrap Text
Announcement of the annual general meeting poll results
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
26 July 2018
ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS
Mediclinic announces that at its Annual General Meeting (“AGM”) held on 25 July 2018, all resolutions set out in the notice of the AGM were passed by the
requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:
TOTAL % OF ISSUED VOTES FOR % VOTES % VOTES
SHARES SHARE CAPITAL AGAINST WITHHELD
VOTED VOTED
ORDINARY RESOLUTIONS
1. To receive the Company’s 625,083,123 84.79 625,071,801 100.00 11,322 0.00 756,974
financial statements and the
reports by the Directors and
auditors
2. To approve the Directors’ 624,930,678 84.77 584,591,036 93.54 40,339,642 6.46 909,418
Remuneration Report
3. To declare a final dividend of 4.70 625,551,249 84.85 625,538,743 100.00 12,506 0.00 288,848
pence per ordinary share
4. To elect Dr Ronnie van der Merwe 625,545,985 84.85 624,986,007 99.91 559,978 0.09 294,112
as a Director
5. To elect Dr Muhadditha Al 625,545,570 84.85 625,118,233 99.93 427,337 0.07 294,527
Hashimi as a Director
6. To elect Dr Felicity Harvey as a 625,546,210 84.85 625,119,604 99.93 426,606 0.07 293,887
Director
7. To re-elect Jurgens Myburgh as a 625,545,985 84.85 624,155,541 99.78 1,390,444 0.22 294,112
Director
8. To re-elect Dr Edwin Hertzog as a 623,687,848 84.60 607,348,527 97.38 16,339,321 2.62 2,152,247
Director
9. To re-elect Jannie Durand as a 625,264,107 84.81 612,530,823 97.96 12,733,284 2.04 575,989
Director
10. To re-elect Alan Grieve as a 622,786,782 84.48 621,642,338 99.82 1,144,444 0.18 3,053,315
Director
11. To re-elect Seamus Keating as a 622,785,782 84.47 622,271,752 99.92 514,030 0.08 3,054,315
Director
12. To re-elect Trevor Petersen as a 622,786,512 84.47 620,324,982 99.60 2,461,530 0.40 3,053,585
Director
13. To re-elect Desmond Smith as a 621,209,703 84.26 551,631,116 88.80 69,578,587 11.20 4,630,393
Director
14. To re-elect Danie Meintjes as a 625,545,985 84.85 603,084,758 96.41 22,461,227 3.59 294,112
Director
15. To re-appoint 622,507,013 84.44 618,004,417 99.28 4,502,596 0.72 3,333,084
PricewaterhouseCoopers LLP as
auditors of the Company
16. To authorise the Audit and Risk 625,265,419 84.81 624,782,389 99.92 483,030 0.08 574,678
Committee to determine the
remuneration of the auditors
17. To authorise the Directors to 624,054,992 84.65 560,842,274 89.87 63,212,718 10.13 1,785,104
make political donations
18. To authorise the Directors to allot 625,265,198 84.81 524,756,458 83.93 100,508,740 16.07 574,899
ordinary shares
SPECIAL RESOLUTIONS
19. To authorise the Directors to dis- 625,262,700 84.81 590,059,495 94.37 35,203,205 5.63 577,397
apply the statutory pre-emption
rights
20. To authorise the Directors to dis- 625,263,385 84.81 591,029,782 94.52 34,233,603 5.48 576,711
apply pre-emption rights for
purposes of acquisitions or capital
investments
21. To approve the reduction in 624,328,189 84.68 602,771,765 96.55 21,556,424 3.45 1,511,908
minimum notice period for general
meetings (other than annual
general meetings)
VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDER ON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS
ORDINARY RESOLUTIONS TOTAL % OF ISSUED VOTES FOR % VOTES % VOTED
SHARES SHARE CAPITAL AGAINST WITHHELD
VOTED VOTED
5. To elect Dr Muhadditha Al 369,163,066 76.77 368,735,729 99.88 427,337 0.12 294,527
Hashimi as a Director
6. To elect Dr Felicity Harvey as a 369,163,706 76.77 368,737,100 99.88 426,606 0.12 293,887
Director
10. To re-elect Mr Alan Grieve as a 366,404,278 76.20 365,259,834 99.69 1,144,444 0.31 3,053,315
Director
11. To re-elect Mr Seamus Keating as 366,403,278 76.20 365,889,248 99.86 514,030 0.14 3,054,315
a Director
12. To re-elect Mr Trevor Petersen as 366,404,008 76.20 363,942,478 99.33 2,461,530 0.67 3,053,585
a Director
13. To re-elect Mr Desmond Smith as 364,827,199 75.87 295,248,612 80.93 69,578,587 19.07 4,630,393
a Director
Notes:
1. Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the "For" total.
2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
3. The Company's total ordinary shares in issue (total voting rights) as at 25 July 2018 was 737 243 810 ordinary shares of 10 pence each.
Ordinary shareholders are entitled to one vote per ordinary share held.
4. As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each
resolution to elect an independent non-executive director (resolutions 5 to 6 and 10 to 13) have under Listing Rule 9.2.2E been approved
by a majority of the votes cast by:
(a) the shareholders of the Company as a whole; and
(b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the
controlling shareholder.
In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage
Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM.
The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Investor Relations section of the Company’s
website at http://ir.mediclinic.com.
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800
inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in
Namibia.”
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 26/07/2018 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
